Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the ...

Now with a better view of how the medication is affecting behavior, packaged-food companies are trying to profit off of the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The State Health Plan's decision to end coverage of certain weight-loss prescription drugs has produced an unlikely and ...

Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...

John Paulson is among the most well-known billionaires, famous for his long-term investing returns via his hedge fund Paulson ...